中國動力(600482.SH):子公司擬將前次募投項目結餘資金1.45億元永久補流
格隆匯7月21日丨中國動力(600482.SH)公佈,風帆公司年產500萬隻免維護電池項目已按照募投項目方案建設完畢並達到預計產能,並結餘資金1.39億元,項目效益體現在公司整體收益中。根據募投方案計劃,該上述結餘資金將優先用於年產400萬隻AGM電池項目。風帆公司結合近年來新能源汽車發展趨勢和自身產能建設情況,不再投資年產400萬隻AGM電池項目,兩個項目結餘資金永久補充風帆公司流動資金。
為進一步提高結餘募集資金使用效率,為公司和股東創造最大的利益,結合公司生產經營需求,擬將上述結餘募集資金1.45億元(含利息收入淨額和未到期工程尾款)永久補充風帆公司流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.